ICRAKI- intermittent vs continuous RRT for AKI in the ICU? VA by @farahwehbe92 #NephTwitter #NephJC nephjc.com/news/icraki-the-v…

🏃‍♂️💀🌼 5.5 km por el Día de Muertos 🇧🇴 Una carrera especial, llena de tradición, energía y buenos momentos. ¡Celebrando la vida, honrando la memoria y sumando kilómetros! 🏃‍♂️✨ #DíaDeMuertos #Running

💊 β-Blockers in Hemodialysis: Does Dialyzability Matter? Nondialyzable β-blockers were associated with fewer cardiovascular events, particularly early after HD initiation. Promising findings, but RCTs are still needed. #Nephrology 🔗 doi.org/10.1681/ASN.00000012…

The media needs trusted kidney experts. Thoughtful engagement by nephrologists can counter misinformation, amplify evidence-based care, raise CKD awareness, and help patients make more informed decisions, according to a #Perspective in #ASNCJASN. kidney.pub/CJASN1262

ISN membership connects you to the latest in kidney science, helping you grow professionally and stay at the forefront of nephrology through valuable resources, opportunities, and a global community committed to advancing kidney care. 📖 This weekend’s @KIReports #ISNFridaySelection is open access: Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease ➡️ bit.ly/4i2OTEC Grow with the ISN. Join/renew your 2027 ISN membership at the new, lower fees ➡️ bit.ly/3QzUx5W #ThisIsISN – Advancing kidney health worldwide. Together.

#SpookyRun 🏃🏻‍♂️ 👻 #GhostRunner #Halloween 🎃

#ASNCJASN: Only 24% of older adults with advanced CKD accurately perceived their kidney failure risk. Fatalism, caregiver burnout, and knowledge gaps remained key barriers, highlighting the need for better risk communication. kidney.pub/CJASN1220

There is still time to share your feedback! The focused update of the KDIGO 2027 CKD Guideline is available for public review through November 4, 2026. Visit the KDIGO CKD Guideline website to download the draft and share your comments via the feedback survey: kdigo.org/guidelines/ckd-eva… The focused update addresses new evidence since publication of the KDIGO 2024 CKD Guideline on SGLT2 inhibitors, GLP-1-based therapies, and nsMRAs in people with CKD, excluding those receiving dialysis or who have received a kidney transplant.

Happy Halloween!

🆕 📑 from Vietnam 🇻🇳 supports the Renal Angina Index for early prediction of severe AKI in critically ill 🧒🏼. In 314 patients, RAI ≥8 showed 78.6% sensitivity and 70.5% specificity, with 7.4-fold higher odds of severe AKI. #AKI #PedsNephrology 🔗 link.springer.com/article/10…

A multicenter study evaluated ML to predict KRT or in-🏥 death in critically ill patients with rhabdomyolysis. External validation showed good discrimination (AUROC 0.89), outperforming McMahon score. Findings support further prospective validation before clinical use.

🔬 Beyond creatinine: Rethinking kidney recovery after AKI Emerging biomarkers may reveal persistent injury, inflammation, adaptive repair & fibrosis—offering new insights into long-term kidney outcomes. Is it time to redefine AKI recovery? 🔗 ovid.com/jnls/co-nephrolhype…

💡 #KidneyWk 2026 offered a valuable opportunity for ERA to strengthen international collaborations and explore new ways to advance nephrology worldwide. 🌍 ERA leadership held fruitful meetings with the Japanese Society of Nephrology (JSN), KDIGO, and the Latin American Society of Nephrology and Hypertension (SLANH), reaffirming a shared commitment to scientific exchange, education and international cooperation. ✍️ A key milestone was the signing of a new Memorandum of Understanding with JSN, marking an important step forward in our partnership. 🤝 These exchanges highlight the importance of working across borders, sharing knowledge and strengthening connections within the global nephrology community. @jsnorjp @goKDIGO @SLANH_

#ASNCJASN: A small, early eGFR dip may be a sign treatment is working. In MIRO-CKD, balcinrenone plus dapagliflozin produced modest, reversible eGFR reductions associated with greater lowering of blood pressure and albuminuria, with no increase in serious safety events. kidney.pub/CJASN1202

🫘 Empagliflozin in ADPKD: A pilot RCT (JASN; n=50) showed good tolerability and an early eGFR dip followed by stabilization, but greater kidney volume increase vs placebo. 🔬 Larger trials needed. 🔗 ovid.com/jnls/jasn/fulltext/…

💊 Drug dosing in post-dilution HDF: Are standard HD doses appropriate? A review highlights the impact of drug properties, convection volume, & post-dialysis rebound on drug clearance. Individualized dosing & therapeutic drug monitoring are essential. 🔗 journals.lww.com/cjasn/fullt…

Promising advances in kidney transplant desensitization! A phase 1 study reports that dual CD19/BCMA CAR-T therapy induced profound but transient B-cell depletion, ⬇️HLA sensitization, & enabled kidney transplantation in 2 highly sensitized patients 🔗DOI: 10.1056/NEJMoa2513428

Resistant hypertension remains a major global challenge. Better BP monitoring, optimized multidrug therapy, and emerging precision treatments are improving how we diagnose and manage this high-risk condition. #Review in #ASNCJASN. kidney.pub/CJASN1266

Congratulations to Robert G. Narins Award recipient Ravindra L. Mehta, MBBS, MD, DM, FASN. His work has helped shape modern acute kidney injury care through advances in AKI classification, fluid management, and continuous kidney replacement therapy. kidney.pub/KN1810-24 #ASNKidneyNews

#kidneywk Day 3 of simultaneous publications covered by #nephjc Until the next time 👋 ✍️@CristinaDeReins @dra_miliflores @DrAkshayaJ @hswapnil @brian_rifkin @kidney_boy nephjc.com/news/denver-day3